Lunaphore, a Swiss med-tech company developing technology for tissue diagnostics, raised a CHF2m Series A funding round.
Redalpine Venture Partners, a seed and early-stage venture investor based in Zurich, led the round with participation from private investors from Switzerland and the UK. Dr. Michael Sidler, co-founder and partner at Redalpine, joined Lunaphore’s Board of Directors.
The company intends to use the funds to bring their products closer to market.
Founded in April 2014 as a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL) by Dr. Ata Tuna Ciftlik, CEO, Lunaphore has developed an innovative tissue diagnostics platform, primarily for analysis and classification of tumors. The platform is based on microfluidic chip technology that allows fine-tuning of such diagnostic assays and increases their speed and accuracy.